ES2157216T3 - Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina. - Google Patents

Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina.

Info

Publication number
ES2157216T3
ES2157216T3 ES93903433T ES93903433T ES2157216T3 ES 2157216 T3 ES2157216 T3 ES 2157216T3 ES 93903433 T ES93903433 T ES 93903433T ES 93903433 T ES93903433 T ES 93903433T ES 2157216 T3 ES2157216 T3 ES 2157216T3
Authority
ES
Spain
Prior art keywords
carbon atoms
independently selected
mammal
alkyl radicals
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93903433T
Other languages
English (en)
Inventor
Charles Gluchowski
Michael E Garst
James A Burke
Larry A Wheeler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ES2157216T3 publication Critical patent/ES2157216T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

UN METODO DE TRATAMIENTO DE UN MAMIFERO COMPRENDE LA ADMINISTRACION A UN MAMIFERO DE UNA CANTIDAD EFECTIVA PARA PROPORCIONAR LOS EFECTOS TERAPEUTICOS DESEADOS EN EL MAMIFERO DE UN COMPUESTO SELECCIONADO DEL GRUPO CONSISTENTE EN AQUELLOS QUE TIENEN LA FORMULA (1), ACIDO FARMACEUTICAMENTE ACEPTABLE EN ADICION A SALES Y MEZCLAS CONSIGUIENTES, EN LA QUE R1 Y R4 SON SELECCIONADOS INDEPENDIENTEMENTE DEL GRUPO CONSISTENTE EN H Y RADICALES ALQUILOS QUE TIENEN DE 1 A 4 ATOMOS DE CARBONO; LOS R2S SON SELECCIONADOS INDEPENDIENTEMENTE DESDE H O RADICALES ALQUILOS QUE TIENEN DE 1 A 4 ATONOS DE CARBONO O SON, JUNTOS, OXO; EL GRUPO 2 Y R7 ESTAN SITUADOS CADA UNO EN UNA DE LAS POSICIONES 5-, 6-, 7 U 8 MENTE SELECCIONADO DEL GRUPO QUE CONSISTE EN CL, BR, H Y RADICALES ALQUILES QUE TIENEN DE 1 A 3 ATOMOS DE CARBONO. DICHOS COMPUESTOS, CUANDO SE ADMINISTRAN A UN MAMIFERO, PROPORCIONAN LOS DESEADOS EFECTOS TERAPEUTICOS TALES COMO REDUCCION DEL DOLOR PERIFERICO, ANESTESIA DEL SISTEMA NERVIOSO CENTRAL, CONSTRICCION DE UN O MAS VASOS SANGUINEOS, REDUCCION O PREVENCION DE AL MENOS UN DE LOS EFECTOS DE LA ISQUEMIA, DESCONGESTION DE UN O MAS ORIFICIOS NASALES Y REDUCCION DE AL MENOS UN EFECTO DE UN DESORDEN INFLAMATORIO.
ES93903433T 1992-01-13 1993-01-12 Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina. Expired - Lifetime ES2157216T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/820,329 US5231096A (en) 1989-10-12 1992-01-13 Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives

Publications (1)

Publication Number Publication Date
ES2157216T3 true ES2157216T3 (es) 2001-08-16

Family

ID=25230500

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93903433T Expired - Lifetime ES2157216T3 (es) 1992-01-13 1993-01-12 Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina.

Country Status (9)

Country Link
US (1) US5231096A (es)
EP (1) EP0620732B1 (es)
JP (1) JPH07503015A (es)
AT (1) ATE200222T1 (es)
AU (1) AU670064B2 (es)
CA (1) CA2127542C (es)
DE (1) DE69330090T2 (es)
ES (1) ES2157216T3 (es)
WO (1) WO1993013771A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5326763A (en) * 1989-10-12 1994-07-05 Allergan, Inc. Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
US6323204B1 (en) * 1993-10-13 2001-11-27 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
WO1995010280A1 (en) * 1993-10-13 1995-04-20 Allergan Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ATE194771T1 (de) * 1993-12-17 2000-08-15 Procter & Gamble 6-(2-imidazolinylamino) chinoxalin-verbindungen als alpha-2-adrenorezeptoragonisten
US5578607A (en) * 1993-12-17 1996-11-26 The Procter & Gamble Company 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
US5576437A (en) * 1993-12-17 1996-11-19 The Procter & Gamble Company 7-(2-imidazolnylamino) quinoline compounds useful as alpha-2 adrenoceptor agonists
US5478858A (en) * 1993-12-17 1995-12-26 The Procter & Gamble Company 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists
BR9408335A (pt) * 1993-12-17 1997-08-19 Procter & Gamble Composto uso do mesmo e composição farmacêutica
DK0693055T3 (da) * 1994-02-08 1997-12-15 Alcon Lab Inc Hidtil ukendt fremgangsmåde til fremstilling af clonidinderivater
US5916900A (en) 1995-06-29 1999-06-29 The Procter & Gamble Company 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
NZ504707A (en) 1997-11-24 2002-11-26 Procter & Gamble 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability
US6329369B1 (en) 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
ATE444732T1 (de) * 2003-08-07 2009-10-15 Allergan Inc Zusammensetzungen zur abgabe von therapeutika in die augen und verfahren zu ihrer herstellung und verwendung
RU2008122978A (ru) 2005-11-09 2009-12-20 Комбинаторкс, Инкорпорейтед (Us) Способы, композиции и наборы для лечения медицинских состояний

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US4908387A (en) * 1988-06-06 1990-03-13 The Regents Of The University Of California Use of beta2 antagonists in the treatment of inflammatory diseases, in particular, rheumatoid arthritis
US5077292A (en) * 1989-10-12 1991-12-31 Allergan, Inc. (2-imidazolin-2-ylamino) tetrahydroquinoxalines and methods for using same
US5112822A (en) * 1989-10-12 1992-05-12 Allergan, Inc. (2-imidazolin-2-ylamino) quinoxaline derivatives and methods for using same
US5021416A (en) * 1989-10-31 1991-06-04 Allergan, Inc. Method for using (2-imidazolin-2-ylamino) quinoxalines to reduce or maintain intraocular pressure

Also Published As

Publication number Publication date
JPH07503015A (ja) 1995-03-30
ATE200222T1 (de) 2001-04-15
AU3470093A (en) 1993-08-03
DE69330090T2 (de) 2001-09-20
CA2127542C (en) 2004-08-03
EP0620732B1 (en) 2001-04-04
US5231096A (en) 1993-07-27
DE69330090D1 (de) 2001-05-10
AU670064B2 (en) 1996-07-04
WO1993013771A1 (en) 1993-07-22
EP0620732A1 (en) 1994-10-26
CA2127542A1 (en) 1993-07-22

Similar Documents

Publication Publication Date Title
CA2173974A1 (en) Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
ES2157216T3 (es) Metodos de utilizacion de derivados de (2-imidazolin-2-ilamino) quinoxalina.
ATE104973T1 (de) (2-imidazolin-2-ylamino)-tetrahydro-chinoxaline und anwendungsverfahren.
IL98735A0 (en) (2-imidazolin-2-ylamino)quinoxaline derivatives and methods for using same
KR940014328A (ko) 인돌린 화합물
KR950016760A (ko) 치질 치료제
NO923413D0 (no) Terapeutiske benzazepin-forbindelser
PT986393E (pt) Utilizacao de um nitroxido ou de um seu pro-farmaco no tratamento profilactico e terapeutico do cancro
NO307406B1 (no) Anvendelse av 1-aryl-3-(4-piperidyl)-indolderivater ved behandling av kognitive forstyrrelser
MY108455A (en) Therapeutic benzazapine compounds.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 620732

Country of ref document: ES